Overview

* LifeMD ( LFMD ) Q3 revenue grows 13% yr/yr but misses analyst expectations

* Adjusted EBITDA for Q3 rises 20% yr/yr but misses analyst expectations

* Company paid off all outstanding debt during the quarter

Outlook

* LifeMD ( LFMD ) forecasts Q4 revenue between $45 mln and $46 mln

* Company expects full-year 2025 revenue of $192 mln to $193 mln

* LifeMD ( LFMD ) anticipates 2025 adjusted EBITDA of $13.5 mln to $14.5 mln

Result Drivers

* TELEHEALTH GROWTH - Telehealth revenue increased 18%, contributing to overall revenue growth

* PLATFORM DIVERSIFICATION - Co is diversifying its clinical platform with new launches in women's health, men's health, and psychiatry

* WORKSIMPLI DIVESTITURE - Divestiture of WorkSimpli stake positions LifeMD ( LFMD ) as a pure-play telehealth and pharmacy platform

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $60.20 $62.06

Revenue mln mln (8

Analysts

)

Q3 EPS -$0.10

Q3 Net -$4.60

Income mln

Q3 Miss $5.10 $6.06

Adjusted mln mln (8

EBITDA Analysts

)

Q3 Gross 88.00%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for LifeMD Inc ( LFMD ) is $12.50, about 63% above its November 14 closing price of $4.63

* The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 60 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)